NASDAQ$AKBA
Akebia Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Akebia's Q4 2021 financial results were reported, showing increased product revenue and collaboration revenue, and the company highlighted its readiness for the potential launch of vadadustat.
Akebia Therapeutics reported Q4 2021 financial results, with total revenue of $59.6 million, driven by net product revenue of $42.1 million and collaboration revenue of $17.5 million. The company's net loss was $70.7 million. Akebia is preparing for the potential launch of vadadustat, pending FDA approval.
- Total revenue for Q4 2021 was $59.6 million, compared to $56.7 million for Q4 2020.
- Net product revenue for Q4 2021 was $42.1 million, a 22% increase compared to $34.6 million for Q4 2020.
- Collaboration revenue for Q4 2021 was $17.5 million, compared to $22.1 million for Q4 2020.
- Net loss for Q4 2021 was $70.7 million, compared to $87.0 million for Q4 2020.
Headline financials
Revenue & EPS history
Akebia · Revenue · Quarterly
$59.6M
Revenue by segment
Akebia · $59.6M total across 2 segments · Q4 2021
- Auryxia$42.1M+21.7%70.6%
- License & other revenue$17.5M-20.8%29.4%
Forward guidance
Akebia expects continued Auryxia revenue growth in 2022 and is preparing for the potential commercial launch of vadadustat, pending FDA approval.
Tailwinds
- Potential approval of vadadustat by the FDA.
- Potential first-in-class commercial launch of vadadustat in the U.S.
- Expectations regarding net product revenue growth for Auryxia in 2022.
- Ability of Akebia’s pre-commercialization activities to ensure patient access for vadadustat.
- Plans to secure reimbursement for vadadustat under TDAPA.
Headwinds
- Timing of any regulatory approvals is uncertain.
- Interactions with the FDA, including reviews and inspections, can impact approval.
- The direct or indirect impact of the COVID-19 pandemic on Akebia’s business, operations, and the markets.
- Potential generic entrants for Auryxia and vadadustat.
- Changes in the economic and financial conditions of the businesses of Akebia and its collaboration partners and vendors.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-2.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-2.1%
Avg return
30 days after
41%
19 / 46 earnings
Positive
+34.4%
Q1 2020
Best reaction
-22.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -20.3% | -20.3% | -36.7% | |
| Q4 2025 | +9.9% | +0.8% | +10.7% | |
| Q3 2025 | -18.4% | -18.1% | -20.1% | |
| Q1 2025 | +6.6% | +0.8% | +61.4% | |
| Q4 2024 | -12.4% | +32.1% | -14.5% | |
| Q3 2024 | -3.0% | -2.5% | +2.5% | |
| Q2 2024 | +0.0% | +20.7% | +21.6% | |
| Q1 2024 | -13.6% | -12.1% | -24.3% | |
| Q4 2023 | +20.6% | +29.8% | +3.5% | |
| Q3 2023 | -16.5% | -15.3% | +3.7% | |
| Q2 2023 | +10.4% | +12.0% | -5.6% | |
| Q1 2023 | -3.7% | +3.7% | +17.4% | |
| Q4 2022 | -22.4% | -33.7% | -47.6% | |
| Q3 2022 | +1.9% | +2.6% | +9.0% | |
| Q2 2022 | +1.0% | +3.6% | -2.8% | |
| Q1 2022 | +11.2% | +16.6% | +15.6% | |
| Q4 2021 | +13.4% | +12.0% | -66.8% | |
| Q3 2021 | -12.3% | -14.4% | -24.6% | |
| Q2 2021 | +10.5% | +6.5% | +22.2% | |
| Q1 2021 | +2.6% | +10.6% | +17.9% | |
| Q4 2020 | -19.2% | -17.5% | -26.2% | |
| Q3 2020 | -7.4% | +0.8% | +19.8% | |
| Q2 2020 | -6.4% | -4.1% | -75.9% | |
| Q1 2020 | +34.4% | +38.3% | +40.6% | |
| Q4 2019 | -13.8% | -27.0% | -13.0% | |
| Q3 2019 | -9.6% | -8.2% | +73.5% | |
| Q2 2019 | +20.5% | +22.4% | +11.2% | |
| Q1 2019 | +1.5% | -0.7% | -26.8% | |
| Q4 2018 | -0.9% | +2.7% | -15.3% | |
| Q3 2018 | +10.3% | -4.2% | +5.0% | |
| Q2 2018 | -18.1% | -22.1% | -20.8% | |
| Q1 2018 | +0.7% | +11.0% | +10.5% | |
| Q4 2017 | -10.6% | -12.6% | -28.9% | |
| Q3 2017 | -12.6% | -12.8% | -8.5% | |
| Q2 2017 | +6.8% | +9.4% | +26.0% | |
| Q1 2017 | -2.3% | +2.2% | +8.2% | |
| Q4 2016 | -12.6% | -9.3% | -11.1% | |
| Q3 2016 | +10.6% | +14.1% | +9.9% | |
| Q2 2016 | -9.6% | -7.4% | -3.8% | |
| Q1 2016 | -8.8% | — | — | |
| Q4 2015 | -2.4% | — | — | |
| Q3 2015 | -16.6% | — | — | |
| Q2 2015 | -16.9% | — | — | |
| Q1 2015 | +3.3% | — | — | |
| Q3 2014 | -3.2% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro